Opthea Limited (AU:OPT)
ASX:OPT
Top Page
Opthea
(Sydney:OPT)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.58
▼(-4.00% Downside)
Action:UpgradedDate:12/30/25
The score is primarily constrained by weak financial performance—minimal/volatile revenue, large ongoing losses, and sustained heavy cash burn with negative equity. Technical indicators show oversold conditions but no confirmed uptrend, while valuation signals are limited by the negative P/E and lack of dividend support.
Positive Factors
Debt Elimination
Eliminating debt reduces financial risk and interest obligations, enhancing financial flexibility and stability for future growth initiatives.
Negative Factors
Negative Equity
Negative equity indicates accumulated losses, posing risks to financial stability and increasing reliance on external funding for operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Elimination
Eliminating debt reduces financial risk and interest obligations, enhancing financial flexibility and stability for future growth initiatives.
Read all positive factors
Opthea (OPT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$738.77M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)4.56
Revenue Growth-80.08%
EPS Growth59.91%
CountryAU
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.26
Shares Outstanding1,367,978,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-3.65
Price to Sales (P/S)29392.74
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$200.00K
Opthea Business Overview & Revenue Model
Company Description
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endot...
How the Company Makes Money
Opthea makes money primarily through the development and commercialization of its proprietary therapeutic candidates. The company generates revenue by licensing its technologies and intellectual property to pharmaceutical partners. Additionally, O...
Opthea Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.00K | 124.67K | 161.16K | 125.05K | 91.98K |
| Gross Profit | 25.00K | 124.67K | -89.31K | -107.42K | -480.00K |
| EBITDA | -123.19M | -199.29M | -223.30M | -99.01M | -50.14M |
| Net Income | -162.79M | -220.24M | -211.88M | -127.99M | -60.79M |
Balance Sheet | |||||
| Total Assets | 56.80M | 188.79M | 148.19M | 87.32M | 184.36M |
| Cash, Cash Equivalents and Short-Term Investments | 48.44M | 172.47M | 133.99M | 64.90M | 157.43M |
| Total Debt | 0.00 | 141.65M | 272.98K | 0.00 | 150.47K |
| Total Liabilities | 257.87M | 264.60M | 156.98M | 17.55M | 4.16M |
| Stockholders Equity | -201.07M | -75.81M | -8.79M | 69.77M | 180.20M |
Cash Flow | |||||
| Free Cash Flow | -158.66M | -161.05M | -179.34M | -98.39M | -61.08M |
| Operating Cash Flow | -158.64M | -161.02M | -179.30M | -98.37M | -61.06M |
| Investing Cash Flow | -13.00K | -33.49K | -32.64K | -23.32K | 880.07K |
| Financing Cash Flow | 34.77M | 243.73M | 248.70M | 236.62K | 156.76M |
Opthea Technical Analysis
Positive
0.60
Price Trends
0.60
Negative
0.60
Negative
0.60
Positive
Market Momentum
<0.01
Neutral
100.00
Negative
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OPT, the sentiment is Positive. The current price of 0.6 is above the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.60, and above the 200-day MA of 0.60, indicating a neutral trend. The MACD of <0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:OPT.
Opthea Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$4.39B | ― | -2.08% | ― | 60.23% | -66.98% | |
56 Neutral | AU$70.05M | -7.57 | -179.37% | ― | ― | 16.61% | |
52 Neutral | AU$2.75B | ― | -14.02% | ― | 198.58% | 3.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$1.17B | -5.54 | -54.37% | ― | ― | -29.93% | |
42 Neutral | AU$738.77M | -4.51 | 132.37% | ― | -80.08% | 59.91% | |
41 Neutral | AU$134.47M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:OPT
Opthea
0.60
0.00
0.00%
AU:CYP
Cynata Therapeutics Limited
0.30
0.15
96.67%
AU:MSB
Mesoblast Limited
2.13
0.51
31.89%
AU:TLX
Telix Pharmaceuticals
12.95
-10.20
-44.06%
AU:CU6
Clarity Pharmaceuticals Ltd.
3.15
1.63
107.24%
AU:RCE
Recce Pharmaceuticals Ltd.
0.47
0.14
42.64%
Opthea Corporate Events
Opthea Simplifies Capital Structure as 4.45 Million Options and Rights Lapse
Jan 15, 2026
Opthea Limited has notified the Australian Securities Exchange that a total of 4,451,086 options and related conditional rights have ceased, comprising 4,000,000 options that expired unexercised on 19 October 2025 and a further 451,086 conditional...
Opthea Grants 41 Million Options to Non-Executive Director Katherine Connell
Dec 22, 2025
Opthea has disclosed a change in director Katherine Connell’s interests following the issue of 41 million unquoted options under the company’s Non-Executive Directors Share and Option Plan, which was approved at the 11 November 2025 an...
Opthea Issues 82 Million Unquoted Options Under Employee Incentive Scheme
Dec 19, 2025
Opthea Limited has issued 82 million unquoted options under an employee incentive scheme, as disclosed in an Appendix 3G filing with the ASX dated 19 December 2025. The options, which carry various expiry dates and exercise prices and are not inte...
Opthea to Host Corporate Update Webinar
Dec 11, 2025
Opthea Limited announced it will provide a corporate update on December 17, 2025, with Executive Chair Jeremy Levin hosting an online webinar for analysts and investors. This update is expected to offer insights into the company’s strategic ...
Opthea Limited Secures Shareholder Approval for Key Resolutions
Nov 11, 2025
Opthea Limited announced the successful passage of all resolutions at its Annual General Meeting, reflecting strong shareholder support. The resolutions included the re-election of directors and the issuance of options under various plans, which a...
Opthea Streamlines Operations and Strengthens Financial Position
Oct 31, 2025
Opthea Limited has simplified its operations and resolved significant financial liabilities by settling with DFA investors, which has clarified its future cash resources. The company has significantly reduced its operating costs, with research and...
Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market
Oct 30, 2025
Opthea Limited has announced its decision to voluntarily delist from the Nasdaq Stock Market while maintaining its listing on the Australian Securities Exchange (ASX). This strategic move is aimed at streamlining operations, reducing costs, and fo...
Opthea Announces Key Management Appointments
Oct 27, 2025
Opthea Limited has announced the appointment of Mr. Hamish George and Ms. Stephanie Vipond as Joint Company Secretaries, with Mr. George also taking on the role of Chief Financial Officer. This change in management is expected to enhance communica...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.